4D Molecular Therapeutics, Inc. (FDMT) Special Call Transcript

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Special Call July 17, 2024 6:30 AM ET

Company Participants

Uneek Mehra - Chief Financial and Business Officer
David Kirn - Chief Executive Officer and Co-Founder
Robert Kim - Chief Medical Officer
Arshad Khanani - Lead Investigator of PRISM Clinical Trial, Sierra Eye Associates

Conference Call Participants

Salveen Richter - Goldman Sachs
Tazeen Ahmad - BofA Securities
Jonathan Miller - Evercore ISI
Gena Wang - Barclays
Clara Dong - Jefferies

Operator

Ladies and gentlemen, thank you for standing by, and welcome to 4D Molecular Therapeutics Webcast Presentation of Interim Data for 4D 150 24-week Landmark Analysis From PRISM Phase II Population Extension Cohort in Broad Wet AMD. As a reminder, today's call is being recorded.

With that, I will hand the call over to Uneek Mehra, Chief Financial and Business Officer, who will make introductory comments.

Uneek Mehra

Thank you, operator. And thank you, everyone, for joining our webcast this morning. We issued a press release describing the 4D-150 PRISM interim results for our population extension cohort earlier today and the recording of this webcast will be accessible in the investors section of the 4DMT website after the completion of this call.

We remind you here, we may be making forward-looking statements. For further details, you can visit our website. With me today are Dr. David Kirn, our Co-Founder and Chief Executive Officer, who will provide introductory remarks; Dr. Bob Kim, our Chief Medical Officer, who will review the program summary and next steps; and Dr. Arshad Khanani from Sierra Eye Associates and a lead principal investigator on the 4D-150 PRISM clinical trial who will discuss the data.

The PRISM interim data for the population extension cohort was presented earlier this morning by Dr. Raj Maturi, a principal investigator in the PRISM study at the ASRS Annual